Trial Profile
Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Lenvatinib (Primary)
- Indications Endocrine gland neoplasms; Medullary thyroid cancer; Paraganglioma; Phaeochromocytoma; Thyroid cancer
- Focus Adverse reactions
- 04 Mar 2024 Status changed from active, no longer recruiting to completed.
- 05 Sep 2023 Planned End Date changed from 30 Nov 2022 to 30 Nov 2023.
- 05 Sep 2023 Planned primary completion date changed from 30 Nov 2022 to 30 Nov 2023.